<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633514</url>
  </required_header>
  <id_info>
    <org_study_id>1508151-6</org_study_id>
    <nct_id>NCT02633514</nct_id>
  </id_info>
  <brief_title>Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma</brief_title>
  <official_title>A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate whether adjuvant radiochemotherapy after incomplete
      resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The previous trials have showed that radiotherapy was significantly associated with prolonged
      OS and chemotherapy is playing an increasing role in treatment of patients with thymoma or
      thymic carcinoma.However,whether patients with thymoma or thymic carcinoma could benefit from
      adjuvant radiochemotherapy after incomplete resection remains controversial. The purpose of
      this study is to investigate whether adjuvant radiochemotherapy after incomplete resection
      can improve survival for thymoma or thymic carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>from registration to disease progression or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>from registration to death as a result of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment- Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Thymoma and Thymic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Radiochemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adjuvant radiochemotherapy after incomplete resection: Cisplatin + Etoposide + Radiotherapy (60Gy / 30FX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiotherapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>adjuvant radiotherapy after incomplete resection: Radiotherapy (60Gy / 30FX)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25mg/m2,iv gtt,d1-3</description>
    <arm_group_label>Radiochemotherapy</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>75mg/m2,iv gtt,d1-3</description>
    <arm_group_label>Radiochemotherapy</arm_group_label>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>60Gy/30Fx</description>
    <arm_group_label>Radiochemotherapy</arm_group_label>
    <arm_group_label>radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        18~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2;
        Pathologically confirmed ; incomplete resection (R1 or R2);have adequate bone marrow,
        hepatic, and renal function;Patients receive incomplete resection within 3 months; Written
        informed consent.

        Exclusion Criteria:

        Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients
        who have malignancy history excluding carcinoma in situ of cervix in the previous five
        years; Active clinical pulmonary infection; Pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kailiang Wu, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kailiang Wu, MD.PhD.</last_name>
    <phone>+86 64175590</phone>
    <phone_ext>86722</phone_ext>
    <email>wukailiang@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xingwen Fan, MD</last_name>
    <phone>+8613651669687</phone>
    <email>wenxingfan@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kailiang Wu</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kailiang Wu, M.D. Ph. D.</last_name>
      <phone>+86 64175590</phone>
      <phone_ext>86722</phone_ext>
      <email>wukailiang@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Kailiang Wu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>thymoma</keyword>
  <keyword>thymic carcinoma</keyword>
  <keyword>adjuvant radiotherapy</keyword>
  <keyword>adjuvant radiochemotherapy</keyword>
  <keyword>incomplete resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

